Literature DB >> 20806940

Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.

Céline Douat-Casassus1, Oleg Borbulevych, Marion Tarbe, Nadine Gervois, Francine Jotereau, Brian M Baker, Stéphane Quideau.   

Abstract

There is growing interest in using tumor associated antigens presented by class I major histocompatibility complex (MHC-I) proteins as cancer vaccines. As native peptides are poorly stable in biological fluids, researchers have sought to engineer synthetic peptidomimetics with greater biostability. Here, we demonstrate that antigenic peptidomimetics of the Melan-A/MART-1(26(27L)-35) melanoma antigen adopt strikingly different conformations when bound to MHC-I, highlighting the degeneracy of T cell recognition and revealing the challenges associated with mimicking native peptide conformation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806940      PMCID: PMC2951488          DOI: 10.1021/jm100683p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models.

Authors:  A Perrakis; T K Sixma; K S Wilson; V S Lamzin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-07-01

Review 2.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

3.  T cell allorecognition via molecular mimicry.

Authors:  Whitney A Macdonald; Zhenjun Chen; Stephanie Gras; Julia K Archbold; Fleur E Tynan; Craig S Clements; Mandvi Bharadwaj; Lars Kjer-Nielsen; Philippa M Saunders; Matthew C J Wilce; Fran Crawford; Brian Stadinsky; David Jackson; Andrew G Brooks; Anthony W Purcell; John W Kappler; Scott R Burrows; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

4.  A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.

Authors:  J S Blanchet; D Valmori; I Dufau; M Ayyoub; C Nguyen; P Guillaume; B Monsarrat; J C Cerottini; P Romero; J E Gairin
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

5.  Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein.

Authors:  A Quesnel; A Zerbib; F Connan; J G Guillet; J P Briand; J Choppin
Journal:  J Pept Sci       Date:  2001-03       Impact factor: 1.905

6.  Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes.

Authors:  P Sliz; O Michielin; J C Cerottini; I Luescher; P Romero; M Karplus; D C Wiley
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

7.  Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Authors:  Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Journal:  J Mol Biol       Date:  2007-07-26       Impact factor: 5.469

8.  T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility.

Authors:  Oleg Y Borbulevych; Kurt H Piepenbrink; Brian E Gloor; Daniel R Scott; Ruth F Sommese; David K Cole; Andrew K Sewell; Brian M Baker
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

9.  Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

Authors:  Paola Nisticò; Imerio Capone; Belinda Palermo; Duilia Del Bello; Virginia Ferraresi; Federica Moschella; Eleonora Aricò; Mara Valentini; Laura Bracci; Francesco Cognetti; Mariangela Ciccarese; Giuseppe Vercillo; Mario Roselli; Emanuela Fossile; Maria Elena Tosti; Ena Wang; Francesco Marincola; Luisa Imberti; Caterina Catricalà; Pier Giorgio Natali; Filippo Belardelli; Enrico Proietti
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

10.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

View more
  3 in total

1.  Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-126(27L)-35.

Authors:  Marion Tarbe; John J Miles; Emily S J Edwards; Kim M Miles; Andrew K Sewell; Brian M Baker; Stéphane Quideau
Journal:  ChemMedChem       Date:  2020-04-06       Impact factor: 3.466

2.  Analysis of the affinity of influenza A virus protein epitopes for swine MHC I by a modified in vitro refolding method indicated cross-reactivity between swine and human MHC I specificities.

Authors:  Shuhua Fan; Yongli Wang; Xian Wang; Li Huang; Yunxia Zhang; Xiaomeng Liu; Wenshuai Zhu
Journal:  Immunogenetics       Date:  2018-07-10       Impact factor: 2.846

3.  Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules.

Authors:  Kyle R Jackson; Dinler A Antunes; Amjad H Talukder; Ariana R Maleki; Kano Amagai; Avery Salmon; Arjun S Katailiha; Yulun Chiu; Romanos Fasoulis; Maurício Menegatti Rigo; Jayvee R Abella; Brenda D Melendez; Fenge Li; Yimo Sun; Heather M Sonnemann; Vladislav Belousov; Felix Frenkel; Sune Justesen; Aman Makaju; Yang Liu; David Horn; Daniel Lopez-Ferrer; Andreas F Huhmer; Patrick Hwu; Jason Roszik; David Hawke; Lydia E Kavraki; Gregory Lizée
Journal:  PNAS Nexus       Date:  2022-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.